ArticlePloS one2018
Comorbidity, disability, and healthcare expenditure of ankylosing spondylitis in Korea: A population-based study.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- All-Cause and Cause-Specific Mortality in Psoriatic Arthritis and Ankylosing Spondylitis: A Systematic Review and Meta-Analysis.Arthritis care & research · 2023Pooled it
- Peripheral vitamin D levels in ankylosing spondylitis: A systematic review and meta-analysis.Frontiers in medicine · 2022Pooled it
- Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis.Rheumatology (Oxford, England) · 2020Pooled it
- Impact of Ankylosing Spondylitis/Diffuse Idiopathic Skeletal Hyperostosis on Postoperative and Patient-Reported Outcomes Following Elective Cervical and Lumbar Surgery.Global spine journal · 2026Article
- Automated grading and diagnosis of sacroiliitis on CT images using a 3D convolutional neural network: a multicenter retrospective study.Scientific reports · 2026Article
- UK Medical Cannabis Registry: An Updated Analysis of Inflammatory Arthritis.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2026Article
- Age, Gender, and Disease Duration as Key Determinants of Comorbidity Burden in Spondyloarthritis: A Multicentre Cross-Sectional Study.Mediterranean journal of rheumatology · 2025Article
- Article
- Incidence rate of and risk factors for glomerulonephritis in patients with axial spondyloarthritis: a nationwide population-based study.Therapeutic advances in musculoskeletal disease · 2025Article
- Epidemiologic Trends and Socioeconomic Disparities of Ankylosing Spondylitis in South Korea: A Nationwide Population-Based Study, 2010-2021.Yonsei medical journal · 2024Article
- Multimorbidity phenotypes in ankylosing spondylitis and their association with disease activity and functional impairment: Data from the prospective study of outcomes in ankylosing spondylitis cohort.Seminars in arthritis and rheumatism · 2024Article
- Real-life data on the comorbidities in spondyloarthritis from our multicenter nationwide registry: BioStar.Archives of rheumatology · 2023Article
- Impact of TNF inhibitor medication on working ability in axial spondyloarthritis: an observational national registry-based cohort study.Rheumatology advances in practice · 2023Article
- The Epidemiology and Treatment of Ankylosing Spondylitis in Korea.Journal of rheumatic diseases · 2022Review
- Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis.Journal of managed care & specialty pharmacy · 2022Article
- Association of particulate matter with autoimmune rheumatic diseases among adults in South Korea.Rheumatology (Oxford, England) · 2021Article
- Real-world experiences of the diagnosis process in Korean patients with ankylosing spondylitis based on a self-report questionnaire.The Journal of international medical research · 2021Article
- Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score-Matched Analysis from the Korean College of Rheumatology Biologics Registry.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020Article
- Risk of immune-mediated inflammatory diseases in newly diagnosed ankylosing spondylitis patients: a population-based matched cohort study.Arthritis research & therapy · 2019Article
- Application of machine learning in the diagnosis of axial spondyloarthritis.Current opinion in rheumatology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnkylosing spondylitis (AS) is an inflammatory rheumatic disease typically diagnosed in young age and follows a chronic progressive course. Its impact on the patient is life-long and the burden that AS exerts on society is increasing cumulatively every year. We aimed to quantify the burden of AS and to identify the factors associated with comorbidity, disability, and healthcare expenditure in Korean AS patients.
methodsWe conducted a nationwide, population-based study using health insurance data (2003-2013). The analysis included individuals with incident AS (1,111 patients) and controls (5,555 patients) matched by age, sex, income, and geographic region. The incidence rates of extra-articular manifestations (EAMs), comorbidities, mortality, and disability (type and severity) were compared between AS patients and controls. Annual health expenditure per patient was also analyzed. Associations were expressed as odds ratios (ORs) with 95% confidence intervals (95%CIs).
resultsDuring the follow-up, 28% of AS patients experienced at least one EAM. AS diagnosis was significantly associated with Charlson comorbidity index ≥3 (OR 2.18, 95% CI 1.91-2.48). Disability rate was higher in AS patients than in controls regardless of cause and severity (OR 2.94, 95% CI 2.48-3.48), but crude incidence rate ratios for mortality were not significantly higher. On multivariate analysis, male sex (OR 3.18, 95% CI 2.13-4.75), presence of an EAM (OR 1.63, 95% CI 1.15-2.32), and older age at diagnosis (OR 1.27, 95% CI 1.20-1.35) were evidently associated with increased disability in AS. Presence of an EAM was also associated with increased AS-unrelated expenditures in biologic-naïve patients (median, 1112 vs. 877 USD per person, P < 0.05).
conclusionsIn patients with AS, demographic factors and systemic manifestations including EAMs and other comorbidities were associated with increased disability and healthcare expenditures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.